ID Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ID Pharma Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10829
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ID Pharma Co Ltd (ID Pharma), formerly DNAVEC Corp is a manufacturer and commercializer of gene medicines. The company develops regenerative medicines, cell therapy and other bio products. It provides vector platforms such as Sendai virus vector in its drug development process. ID Pharma’s vector technology is used to develop drugs in the bio-business classes such as gene therapy, gene vaccine, antibody, protein production and gene function analysis, among others. The company develops gene therapies for cardiovascular, respiratory, autoimmune, ophthalmologic diseases, cancer, and others. Its gene vaccines are used for the treatment of tuberculosis, influenza, malaria, Alzheimer’s disease, tumor and Parkinson’s disease, among others. The company has operations in the US, Japan and China. ID Pharma is headquartered in Tokyo, Japan.

ID Pharma Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ID Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ID Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Life Technologies Extends R&D Agreement With Dnavec For CytoTune-iPS 2.0 Sendai Reprogramming Kit 11
Licensing Agreements 12
Q-State Biosciences Enters into Licensing Agreement with ID Pharma 12
Axol Boscience Enters into Licensing Ageement with ID Pharma 13
Elixirgen Enters into Licensing Agreement with ID Pharma 14
Mayo Clinic Enters into Licensing Agreement with ID Pharma 15
Newcells Biotech Enters into Licensing Agreement with ID Pharma 16
Minerva Biotech Enters into Licensing Agreement with ID Pharma 17
Medinet Enters into Licensing Agreement with ID Pharma 18
Kohjin Bio to Enter into Licensing Agreement with ID Pharma 19
Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 20
DNAVEC Enters Into Licensing Agreement With RIKEN BioResource Center 21
ID Pharma Co Ltd – Key Competitors 22
ID Pharma Co Ltd – Key Employees 23
ID Pharma Co Ltd – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Joint Venture 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ID Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ID Pharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
ID Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Life Technologies Extends R&D Agreement With Dnavec For CytoTune-iPS 2.0 Sendai Reprogramming Kit 11
Q-State Biosciences Enters into Licensing Agreement with ID Pharma 12
Axol Boscience Enters into Licensing Ageement with ID Pharma 13
Elixirgen Enters into Licensing Agreement with ID Pharma 14
Mayo Clinic Enters into Licensing Agreement with ID Pharma 15
Newcells Biotech Enters into Licensing Agreement with ID Pharma 16
Minerva Biotech Enters into Licensing Agreement with ID Pharma 17
Medinet Enters into Licensing Agreement with ID Pharma 18
Kohjin Bio to Enter into Licensing Agreement with ID Pharma 19
Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 20
DNAVEC Enters Into Licensing Agreement With RIKEN BioResource Center 21
ID Pharma Co Ltd, Key Competitors 22
ID Pharma Co Ltd, Key Employees 23
ID Pharma Co Ltd, Other Locations 24
ID Pharma Co Ltd, Joint Venture 24

List of Figures
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ID Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ID Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[ID Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mondelez International Inc (MDLZ):企業の財務・戦略的SWOT分析
    Mondelez International Inc (MDLZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Achaogen Inc (AKAO):企業財務及び戦略的SWOT分析
    Summary Achaogen Inc (Achaogen) discovers, develops and commercializes novel anti bacterials for the treatment of multi-drug resistant and gram-negative infections. The company’s pipeline product portfolio includes plazomicin, which is a phase III clinical trial stage compound for the treatment of b …
  • SeraCare Life Sciences, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' SeraCare Life Sciences, Inc. Me …
  • General Communication, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' General Communication, Inc. Mer …
  • Beijing Tiantan Biological Products Co., Ltd. (600161):企業概要、財務及び戦略的SWOT分析
    Summary Beijing Tiantan Biological Products Co., Ltd. (Tiantan Biological) is a biotechnology company. The company research, develops, manufactures and sells vaccines for viral and bacterial infections. It concentrates on vaccines, blood products and diagnostic reagents for research and development, …
  • New World Resources Plc:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' New World Resources Plc Mergers …
  • GS Yuasa Corporation (6674):企業の財務・戦略的SWOT分析
    GS Yuasa Corporation (6674) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • N2N Connect Berhad (N2N):企業の財務及び戦略的SWOT分析
    Summary N2N Connect Berhad (N2N Connect) is a technology company that develops software packages and provides design, programming and consultancy services. The company’s products include TCProGlobal, TCPlus, TCMobile, TCM2, TCPair and TCBOS. It offers software solutions for capital market applicatio …
  • Nanotherapeutics, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Nanotherapeutics, Inc. Mergers …
  • Medgenics Inc. (MDGN):企業の財務及び戦略的SWOT分析
    Summary Medgenics Inc. (Medgenics) is a biopharmaceutical company that discovers, develops and commercializes new therapies platform for treating patients with rare genetic and orphan diseases. The company’s products under clinical development includes MDGN-201, MDGN-204, MDGN-205 and MDGN-206. Its …
  • Pivot3, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Pivot3, Inc. Mergers and Acquis …
  • Erin Energy Corporation (ERN):企業の財務及び戦略的SWOT分析
    Summary Erin Energy Corporation (Erin Energy), formerly CAMAC Energy Inc., is an oil and gas exploration company that finds and produces oil in sub-Saharan Africa. The company’s projects include offshore exploration projects in Gambia, Ghana and Nigeria. It also has an onshore and offshore project i …
  • wpd onshore GmbH & Co. KG:企業のM&A・提携動向(発電分野)
    Summary wpd onshore GmbH & Co. KG (wpd) is a renewable energy service provider that specializes in the development and financial structuring of both onshore and offshore wind farms and solar energy projects. The company’s portfolio of services include project development, business concept; finance; …
  • Waste Management, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Waste Management, Inc. Mergers …
  • KSS Line Ltd. (044450):企業の財務及び戦略的SWOT分析
    Summary KSS LINE LTD. (KSS), formerly Korea Special Shipping Co., Ltd is a marine transportation company that operates tanker vessels, and handles gas and chemical cargoes such as liquefied petroleum gas, and liquid petrochemical. The company’s business areas include gas business, chemical business …
  • Metabolon Inc:医療機器:M&Aディール及び事業提携情報
    Summary Metabolon Inc (Metabolon) is a health technology company that develops clinical diagnostic tests for healthcare markets. The company’s products include non-alcoholic steatohepatitis test, GFR test, quantose IGT test, prostarix and prostarix plus tests, among others. Its quantose IR test is a …
  • Torstar Corporation (TS.B):企業概要、財務及び戦略的SWOT分析
    Summary Torstar Corporation (Torstar) is a progressive media company. The company operates in daily and community newspapers, book publishing, women’s fiction magazines and digital businesses. It operates through Media and Book Publishing segments. Torstar publishes more than 120 newspapers and oper …
  • PharmAthene Inc (PIP):企業財務及び戦略的SWOT分析
    Summary PharmAthene Inc (PharmAthene) is a pharmaceutical company that develops and commercializes medical counter measures to biological and chemical weapons. The company’s products include recombinant protective antigen anthrax vaccine, human monoclonal antibody antitoxin and recombinant BChE bios …
  • Microvision, Inc. (MVIS):企業のM&A・提携動向(医療機器分野)
    Summary Microvision, Inc. (Microvision) is a medical device company that offers scanning technology solutions. The company offers PicoP scanning technology, an ultra-miniature laser projection and imaging solution based on the laser beam scanning methodology. It also offers consumer displays, vehicl …
  • Ashmore Energy International:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Ashmore Energy International Me …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆